Arcellx Research Development from 2010 to 2026

Stocks . USA . 
Stock . Arcellx
ACLX Stock  USD 114.29  -0.07  -0.06%   
Arcellx's Research Development has experienced a moving upward cycle characterized by slightly volatile volatility. Compared with the previous period, Research Development is down roughly 65.66%, indicating near-term softness. Over multiple reporting cycles from 2010 to 2026, regression modeling generated a r-value value of 0.81 . with r-squared of 0.66 . View All Fundamentals
 
Research Development  
 First Reported
2020-12-31
 Previous Quarter
35.1 M
 Current Value
34.1 M
 Quarterly Volatility
17.5 M
Macro event markers
 
Covid
 
Interest Hikes
Use the financial statements timeline for Arcellx to frame performance drivers and balance sheet structure. It connects Depreciation And Amortization of 7 M, Interest Expense of 25.4 M or Selling General Administrative of 123.6 M and ratios such as Price To Sales Ratio of 173, Dividend Yield of 0.0 or PTB Ratio of 9.58 with Arcellx Valuation and Volatility context.
  
Build AI portfolio with Arcellx Stock
Use Arcellx Correlation to compare Arcellx against competitors. This provides competitive positioning context.
Our How to Invest in Arcellx guide provides practical guidance on trading Arcellx Stock.
Analyzing Arcellx's Research Development over time reveals critical patterns in financial health and operational efficiency. This metric helps investors evaluate trends, identify inflection points, and make informed decisions based on historical performance. Understanding how Research Development has evolved provides context for assessing Arcellx's current valuation and future prospects.

Latest Arcellx's Research Development Growth Pattern

Below is the plot of the Research Development of Arcellx over the last few years. It is Arcellx's Research Development historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Arcellx's overall financial position and show how it may be relating to other accounts over time.
Research Development10 Years Trend
Slightly volatile
Compare to OthersAll Fundamentals
   Research Development   
       Timeline  

Arcellx Research Development Regression Statistics

Arithmetic Mean 49,174,158
Geometric Mean 19,729,090
Coefficient Of Variation 125.73
Mean Deviation 52,632,576
Median 6,112,000
Standard Deviation 61,824,440
Sample Variance3822.3T
Range151.5M
R-Value 0.81
Mean Square Error1382.5T
R-Squared 0.66
Significance 0.000073
Slope 9,953,217
Total Sum of Squares61156.2T

Arcellx Research Development History

202695.1 M
2025157.6 M
2024157.1 M
2023133.8 M
2022149.6 M
202146.9 M
202025.1 M

Stock Overview, Methodology & Data Sources

The stock is undergoing a sell-off trend.Arcellx, Inc., a clinical-stage biotechnology company, engages in the development of various immunotherapies for patients with cancer and other incurable diseases. Arcellx, Inc. was incorporated in 2014 and is headquartered in Gaithersburg, Maryland. Arcellx operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 78 people. This overview emphasizes how Arcellx compares to peers on valuation quality and operating consistency. Current metrics include P/B of 16.62. Arcellx has a market cap of 6.68 B, ROE of -53.42%.

Methodology

Unless otherwise specified, financial data for Arcellx is derived from periodic company reporting (annual and quarterly where available). Asset-level metrics are computed daily by Macroaxis LLC and refreshed regularly based on asset type. Arcellx (USA Stocks:ACLX) prices are typically delayed by approximately 20 minutes from primary exchanges for listed equities. Data may be delayed depending on reporting sources and market conventions. Assumptions: We primarily rely on public filings and market reference sources, including disclosures published by U.S. Securities and Exchange Commission (SEC) via EDGAR and the U.S. Patent & Trademark Office (USPTO). Data is normalized for analytical consistency across reporting formats. All analytics are generated using standardized, rules-based models designed to promote consistency and comparability across instruments. Model assumptions, reference parameters, and selected computational inputs are available in the Model Inputs section. If you have questions about our data sources or methodology, please contact Macroaxis Support.

Analyst Sources

Arcellx is covered by 18 analysts. 9 analysts have submitted revenue and/or earnings estimates that may be incorporated into Macroaxis consensus inputs where available. Representative analyst firms may include Morgan Stanley, Oppenheimer & Co., RBC Capital Markets, J.P. Morgan, Wells Fargo Securities, Guggenheim Securities, Deutsche Bank, Raymond James, Citigroup, HSBC Global Research, among others. Updates may occur throughout the day.

This content is curated and reviewed by:

Gabriel Shpitalnik - Member of Macroaxis Editorial Board

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.
MSFTMicrosoft
CCitigroup
WDWalker Dunlop

More Resources for Arcellx Stock Analysis

A comprehensive view of Arcellx starts with financial statements and ratio context. Key ratios help frame profitability, efficiency, and growth context for Arcellx Stock. Key reports that frame Arcellx Stock are listed below:
How To Invest In Arcellx
Details
Is Arcellx Stock a good investment?
Details
What is Arcellx's Net Worth?
Details
Largest Biotechnology Companies
View
Largest Pharmaceuticals, Biotechnology & Life Sciences Companies
View
Use Arcellx Correlation to compare Arcellx against competitors. This provides competitive positioning context.
Our How to Invest in Arcellx guide provides practical guidance on trading Arcellx Stock.
Analysis related to Arcellx should be read together with other portfolio and risk tools before capital is reallocated. That is especially important when the goal is to improve the overall mix of instruments already held. You can also try the Analyst Advice module to analyst recommendations and target price estimates broken down by several categories.
 Earnings Share
-4.07
 Revenue Per Share
0.396
 Quarterly Revenue Growth
-0.89
 Return On Assets
-0.24
 Return On Equity
-0.53
Understanding Arcellx includes distinguishing between market value and book value, where book value reflects Arcellx's accounting equity. Arcellx's market capitalization is 6.68 B. With a P/B ratio of 16.62, the market values Arcellx well above its book equity. Enterprise value stands at 6.29 B. Intrinsic value represents an estimate of underlying worth and can differ from both market price and book value. Valuation methods compare these perspectives to frame context.
Altman
Z Score
Details
Piotroski
F Score
Details
Beneish
M Score
Details
Financial
Analysis
Details
Buy or Sell
Analysis
Details
Earnings
Projections
Details
It is useful to distinguish Arcellx's value from its trading price, which are computed with different methods. For Arcellx, key inputs include a P/B ratio of 16.62, ROE of -53.42%, and revenue of 22.29 M. By contrast, market price reflects the level where buyers and sellers transact.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY